164 related articles for article (PubMed ID: 30213398)
1. Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA.
Melani C; Wilson WH; Roschewski M
Best Pract Res Clin Haematol; 2018 Sep; 31(3):285-292. PubMed ID: 30213398
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
Kwok M; Wu SP; Mo C; Summers T; Roschewski M
Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
Kurtz DM; Scherer F; Jin MC; Soo J; Craig AFM; Esfahani MS; Chabon JJ; Stehr H; Liu CL; Tibshirani R; Maeda LS; Gupta NK; Khodadoust MS; Advani RH; Levy R; Newman AM; Dührsen U; Hüttmann A; Meignan M; Casasnovas RO; Westin JR; Roschewski M; Wilson WH; Gaidano G; Rossi D; Diehn M; Alizadeh AA
J Clin Oncol; 2018 Oct; 36(28):2845-2853. PubMed ID: 30125215
[TBL] [Abstract][Full Text] [Related]
4. [The role of PET/CT investigation in the management of patients with diffuse large B-cell lymphoma].
Paksi M; Demeter J; Szabó P
Magy Onkol; 2016 Jun; 60(2):108-17. PubMed ID: 27275637
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
Wu FT; Lu L; Xu W; Li JY
Ann Hematol; 2019 Feb; 98(2):255-269. PubMed ID: 30368587
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
Cherng HJ; Herrera A
Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
[TBL] [Abstract][Full Text] [Related]
7. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
Huntington SF; Svoboda J; Doshi JA
J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma.
Hu R; Winter A; Hill BT
Curr Oncol Rep; 2019 Apr; 21(5):44. PubMed ID: 30941515
[TBL] [Abstract][Full Text] [Related]
10. Current status of the role of PET imaging in diffuse large B-cell lymphoma.
Moskowitz CH; Schöder H
Semin Hematol; 2015 Apr; 52(2):138-42. PubMed ID: 25805593
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.
Roschewski M; Dunleavy K; Pittaluga S; Moorhead M; Pepin F; Kong K; Shovlin M; Jaffe ES; Staudt LM; Lai C; Steinberg SM; Chen CC; Zheng J; Willis TD; Faham M; Wilson WH
Lancet Oncol; 2015 May; 16(5):541-9. PubMed ID: 25842160
[TBL] [Abstract][Full Text] [Related]
13. Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma.
Mylam KJ; Nielsen AL; Pedersen LM; Hutchings M
PET Clin; 2014 Oct; 9(4):443-55, vi. PubMed ID: 26050946
[TBL] [Abstract][Full Text] [Related]
14. Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma.
Huntington SF; Nasta SD; Schuster SJ; Doshi JA; Svoboda J
Leuk Lymphoma; 2015; 56(9):2579-84. PubMed ID: 25629993
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET for Early Response Assessment in Lymphomas: Part 2-Diffuse Large B-Cell Lymphoma, Use of Quantitative PET Evaluation.
Cheson BD; Kostakoglu L
Oncology (Williston Park); 2017 Jan; 31(1):71-76. PubMed ID: 28090627
[TBL] [Abstract][Full Text] [Related]
16. Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful.
Shah HJ; Keraliya AR; Jagannathan JP; Tirumani SH; Lele VR; DiPiro PJ
Korean J Radiol; 2017; 18(1):54-70. PubMed ID: 28096718
[TBL] [Abstract][Full Text] [Related]
17. [Research progress on 18F-FDG PET/CT in evaluating prognosis of patient with diffuse large B cell lymphoma].
Yang Y; Zhu HY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):255-60. PubMed ID: 25687083
[TBL] [Abstract][Full Text] [Related]
18. Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation.
Epperla N; Shah N; Hamadani M; Richardson K; Kapke JT; Patel A; Teegavarapu SP; Carrum G; Hari PN; Pingali SR; Karmali R; Fenske TS
Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):672-678. PubMed ID: 27660080
[TBL] [Abstract][Full Text] [Related]
19. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
[TBL] [Abstract][Full Text] [Related]
20. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]